Literature DB >> 6272688

Complementation characteristics of newly isolated mutants from two groups of strains of Clostridium perfringens.

T Imagawa, T Tatsuki, Y Higashi, T Amano.   

Abstract

1. Mutants of a group were converted to b group by a second NG treatment. The resulting b group mutants could not produce the marker products that had been lost on the first NG treatment but could produce the others by complementation. 2. Mutants of b group were converted to constitutive mutants by a second NG treatment. No back mutation from b group was observed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6272688

Source DB:  PubMed          Journal:  Biken J        ISSN: 0006-2324


  6 in total

Review 1.  Molecular genetics and pathogenesis of Clostridium perfringens.

Authors:  J I Rood; S T Cole
Journal:  Microbiol Rev       Date:  1991-12

2.  An upstream regulatory sequence stimulates expression of the perfringolysin O gene of Clostridium perfringens.

Authors:  T Shimizu; A Okabe; J Minami; H Hayashi
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

3.  Virulence gene regulation by the agr system in Clostridium perfringens.

Authors:  Kaori Ohtani; Yonghui Yuan; Sufi Hassan; Ruoyu Wang; Yun Wang; Tohru Shimizu
Journal:  J Bacteriol       Date:  2009-04-10       Impact factor: 3.490

4.  The virR gene, a member of a class of two-component response regulators, regulates the production of perfringolysin O, collagenase, and hemagglutinin in Clostridium perfringens.

Authors:  T Shimizu; W Ba-Thein; M Tamaki; H Hayashi
Journal:  J Bacteriol       Date:  1994-03       Impact factor: 3.490

Review 5.  Regulation of Toxin Production in Clostridium perfringens.

Authors:  Kaori Ohtani; Tohru Shimizu
Journal:  Toxins (Basel)       Date:  2016-07-05       Impact factor: 4.546

6.  Functional analysis of the VirSR phosphorelay from Clostridium perfringens.

Authors:  Jackie K Cheung; Milena M Awad; Sheena McGowan; Julian I Rood
Journal:  PLoS One       Date:  2009-06-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.